Amivantamab extends PFS vs osimertinib
- A post-hoc MARIPOSA analysis presented April 17 at AACR 2026 found first-line amivantamab plus lazertinib was linked to longer second-line progression-free survival than osimertinib in EGFR-mutant advanced non-small cell lung cancer. - Among patients who started subsequent therapy, median second-line progression-free survival was 8.4 months with amivantamab-lazertinib versus 5.3 months with osimertinib, a hazard ratio of 0.72 after 37.9 months of follow-up. - The readout adds to MARIPOSA’s earlier first-line and overall-survival wins as doctors weigh sequencing after August 2024 U.S. approval. (aacrjournals.org) (accessdata.fda.gov)
Some lung cancers are driven by EGFR, a growth signal stuck in the “on” position, and doctors often try to shut that signal down with targeted drugs. (accessdata.fda.gov) In that setting, a new AACR 2026 analysis says the choice of first drug can shape what happens after the cancer starts growing again. (aacrjournals.org) Researchers reported April 17 that patients who started with amivantamab plus lazertinib had longer second-line progression-free survival than patients who started with osimertinib in the phase 3 MARIPOSA trial. (aacrjournals.org) (onclive.com) Second-line progression-free survival measures the time from the start of the next treatment until the cancer grows again or the patient dies. It is a way to ask whether an earlier treatment leaves patients in better shape for what comes next. (aacrjournals.org) Among patients who went on to a first subsequent therapy, median second-line progression-free survival was 8.4 months after amivantamab-lazertinib and 5.3 months after osimertinib. The hazard ratio was 0.72, with a 95% confidence interval of 0.54 to 0.95 and a nominal P value of.02. (aacrjournals.org) (onclive.com) The analysis used a December 4, 2024, data cutoff and included 154 patients who received subsequent therapy after amivantamab-lazertinib and 209 after osimertinib. Median follow-up for those patients was 37.9 months. (aacrjournals.org) Most patients in both groups moved on to regimens that included platinum chemotherapy or another EGFR-directed treatment. OncLive reported those rates as 52% versus 66% for platinum and 47% versus 32% for EGFR-directed therapy in the combination and osimertinib arms, respectively. (onclive.com) The biology may help explain the split. The AACR abstract says amivantamab-lazertinib reduced acquired MET amplification and EGFR resistance mutations versus osimertinib, without a significant increase in other resistance pathways. (aacrjournals.org) MARIPOSA had already shown first-line benefits for the combination, including better progression-free survival than osimertinib. Johnson & Johnson said in March 2025 that the trial also met overall survival, with a reported hazard ratio of 0.75. (aacrjournals.org) (jnj.com) The regimen is already part of routine care. FDA review records show lazertinib with amivantamab was approved in August 2024 for first-line treatment of locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R mutations. (accessdata.fda.gov) What doctors still need is a cleaner map of resistance after each sequence of treatment. This AACR readout suggests that starting with amivantamab plus lazertinib can change not just the first response, but the shape of the next one too. (aacrjournals.org)
